BTG Signs Agreement with Novacea and KuDOS for AQ4N

BTG Signs Agreement with Novacea and KuDOS for AQ4N

BTG Signs Agreement with Novacea and KuDOS for AQ4N

London, UK 19 April 2007: BTG plc (LSE: BGC), the medical innovations company, today announces that it has signed an agreement with Novacea, Inc. (Novacea) and KuDOS Pharmaceuticals Ltd (KuDOS), a wholly owned subsidiary of AstraZeneca UK Ltd, regarding the anti-cancer pro-drug AQ4N.

Under the terms of the agreement, BTG will receive a signature fee and Novacea gains additional rights to AQ4N, so that it now has exclusive worldwide rights to develop and commercialise AQ4N. BTG is also entitled to future milestone and royalty payments.

In 2002, BTG licensed AQ4N to KuDOS, which in 2003 licensed North American rights to AQ4N to Novacea.

Louise Makin, BTG’s chief executive officer, commented: “We are pleased with this agreement and with Novacea’s commitment to the continued development of this promising cancer agent.”

John P. Walker, interim chief executive officer of Novacea, said: “We are pleased to have reached agreement with AstraZeneca and BTG on acquiring the worldwide rights for AQ4N. The extensive pre-clinical and clinical data generated to date gives us confidence in the significant opportunity AQ4N presents as an anti-cancer agent in multiple tumour types and haematological malignancies. As reported this week at the American Association for Cancer Research, investigators presented new and important pre-clinical evidence that AQ4N in combination with mitoxantrone is able to permeate deeply within all tumour types and selectively accumulates in hypoxic tumour cells. This agreement will allow us to manage all strategic development and resource decisions in support of AQ4N.”

About AQ4N

AQ4N is a novel, tumour-selective pro-drug with potential applicability to multiple tumour types, both in combination with a number of chemotherapeutic agents and as a monotherapy for haematological malignancies. AQ4N is an inert, oxidised derivative of AQ4, a well-characterised Topoisomerase II inhibitor which exhibits potent cytotoxicity comparable to other marketed Topoisomerase II inhibitors such as Novantrone® (mitoxantrone) and Adriamycin® (doxorubicin). In November 2006, Novacea initiated a multi-centre Phase 1b/2a open-label clinical study of AQ4N in combination with radiotherapy and temozolomide in patients who were newly diagnosed with glioblastoma multiforme (GBM).

For further information contact

BTG

Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605

Christine Soden, Chief Financial Officer
+44 (0)20 7575 1591; Mobile: +44 7710 484199

Financial Dynamics

Ben Atwell/Anna Keeble
+44 (0)20 7831 3113

About BTG

BTG in-licenses, develops and commercialises pharmaceuticals and other medical technologies. With a substantial and growing revenue stream of royalties and milestone payments from out-licensed products, BTG continues to strengthen its pipeline of preclinical and clinical development programmes. Active in the fields of oncology, diseases of ageing, neuroscience, drug repositioning and medical devices, BTG works from its offices in London, Philadelphia and Osaka with a global partner network of healthcare companies and research organisations.

Back to press releases